Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system

被引:23
|
作者
Zimmerman, Robert S. [1 ]
Hobbs, Todd M. [2 ]
Wells, Brian J. [3 ]
Kong, Sheldon X. [2 ]
Kattan, Michael W. [4 ]
Bouchard, Jon [2 ]
Chagin, Kevin M. [4 ]
Yu, Changhong [4 ]
Sakurada, Brian [2 ]
Milinovich, Alex [4 ]
Weng, Wayne [2 ]
Bauman, Janine M. [4 ]
Pantalone, Kevin M. [1 ]
机构
[1] Cleveland Clin, Endocrinol, Cleveland, OH 44106 USA
[2] Novo Nordisk, Plainsboro, NJ USA
[3] Wake Forest Sch Med, Clin & Translat Sci Inst, Winston Salem, NC USA
[4] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH 44106 USA
来源
DIABETES OBESITY & METABOLISM | 2017年 / 19卷 / 11期
关键词
glucagon-like peptide-1 receptor agonist; cardiovascular risk; cardiovascular disease; mortality; type-2; diabetes; PROTAMINE HAGEDORN INSULIN; TO-TARGET TRIAL; GLYCEMIC CONTROL; BASAL INSULIN; COMBINATION THERAPY; PLUS METFORMIN; NPH INSULIN; GLARGINE; PREDICTORS; HYPOGLYCEMIA;
D O I
10.1111/dom.12969
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To assess the potential impact of glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure on cardiovascular disease (CVD) and mortality outcomes in patients with type 2 diabetes (T2D), using a large retrospective cohort. Research Design and Methods: Patients who had T2D between 2005 and 2014 (N = 105 862) were identified from the electronic health record system at Cleveland Clinic using a validated electronic phenotype. A time-dependent, Cox, multiple regression analysis was used to assess the association between GLP-1RA exposure and risk of acute myocardial infarction (AMI), stroke/cerebrovascular accident (CVA), and overall mortality, as well as the composite of all three outcomes. The findings were further evaluated by assessing the effect of GLP-1RAs on the same variables in patients with and without prior CVD. The model adjusted for differences in demographic information, hypertension, laboratory/vital signs, history of outcomes, and T2D medications. Results: There were significantly lower rates of AMI (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.65 to 0.99; P =.045), CVA (HR 0.82, 95% CI 0.74 to 0.91, P <.001), overall mortality (HR 0.48, 95% CI 0.41 to 0.57; P <.001), and the composite outcome (HR 0.82, 95% CI 0.74 to 0.91; P <.002) during the consolidated time that patients were exposed to GLP-1RAs compared to corresponding rates during intervals without GLP-1RA exposure. GLP-1RA treatment was associated with a significant decrease in CVA, mortality, and the composite outcome in patients with and without established CVD, not significantly affecting AMI in these subgroups. Conclusions: GLP-1RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
引用
下载
收藏
页码:1555 / 1561
页数:7
相关论文
共 50 条
  • [31] Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
    Katherine A. Lyseng-Williamson
    Clinical Drug Investigation, 2019, 39 : 805 - 819
  • [32] Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    Hansen, K. B.
    Knop, F. K.
    Holst, J. J.
    Vilsboll, T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (08) : 1154 - 1160
  • [33] Glucagon-Like Peptide-1 Receptor Agonists Reduction in Stroke Type 2 DM Patients
    Alhawyan, Fatmah Salem
    Althobaiti, Mohammed Adel
    Alnami, Hashim Yahya
    Allahafi, Hadeel Ibrahim
    Almalky, Ayman Jamaan
    Al Johani, Sultan Ahmed
    Shiban, Rokayah Hussain
    Saddah, Mohammed Ahmed
    Alamrah, Hussam Mohammed
    Aljuhani, Moayad Zeyad
    Alfallaj, Ebtehal Hamid
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND PHYTOPHARMACOLOGICAL RESEARCH, 2020, 10 (05): : 122 - 128
  • [34] Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine
    Tang, Hsin-Chieh
    Chen, Calvin Yu-Chian
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 2014
  • [35] Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
    Boye, Kristina S.
    Riddle, Matthew C.
    Gerstein, Hertzel C.
    Mody, Reema
    Garcia-Perez, Luis-Emilio
    Karanikas, Chrisanthi A.
    Lage, Maureen J.
    Riesmeyer, Jeffrey S.
    Lakshmanan, Mark C.
    DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1299 - 1304
  • [36] Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease A Review
    Honigberg, Michael C.
    Chang, Lee-Shing
    McGuire, Darren K.
    Plutzky, Jorge
    Aroda, Vanita R.
    Vaduganathan, Muthiah
    JAMA CARDIOLOGY, 2020, 5 (10) : 1182 - 1190
  • [37] Elevated Glucagon-like Peptide-1 Receptor Level in the Paraventricular Hypothalamic Nucleus of Type 2 Diabetes Mellitus Patients
    Renner, Eva
    Dora, Fanni
    Oszwald, Erzsebet
    Dobolyi, Arpad
    Palkovits, Miklos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [38] Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients
    ten Kulve, Jennifer S.
    van Bloemendaal, Liselotte
    Balesar, Rawien
    IJzerman, Richard G.
    Swaab, Dick F.
    Diamant, Michaela
    la Fleur, Susanne E.
    Alkemade, Anneke
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (05): : 2122 - 2129
  • [39] Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review
    Widiarti, Wynne
    Sukmajaya, Alverina Cynthia
    Nugraha, David
    Alkaff, Firas Farisi
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (03) : 837 - 843
  • [40] Acute plasma amylase increase after glucagon-like peptide-1 receptor agonist exenatide administration in Type 2 diabetes
    Smits, M. M.
    Tonneijck, L.
    Muskiet, M. H. A.
    Diamant, M.
    Kramer, M. H. H.
    Cahen, D. L.
    van Raalte, D. H.
    DIABETIC MEDICINE, 2017, 34 (04) : 591 - 592